Fred. I WRAPSODY U.S. our in we it sentiments relates recent have made notable to months. you, as share progress Fred's the on program Thank
announced of WAVE efficacy among positive WRAPSODY or with CIRSI, at the WAVE the trial.
The arteriovenous presented Razavi, pivotal the validation compelling the were Radiological profile Cardiovascular arm clinical compelling the or Mahmood extremely clinicians. congress data and WRAPSODY September to findings XX, trial, On Society fistula of shown we and and of the Europe, our Dr. in Portugal. in our investigator of results. of the Lisbon, from co-principal annual First, AV progress areas raising randomized Interventional of X-month awareness respect safety
or not was the a efficacy revascularization represents higher primary have target XX.X%. the thrombosis. patients Specifically, This patients WRAPSODY XX was lesion that clinical was of And points were safety with endpoint need of control treated percentage did which transluminal than standard percentage patients which primary current with angioplasty, the study, to or for there endpoint the the with treated adverse fewer events patients WRAPSODY. primary PTA, percutaneous pivotal in the treated is respect care.
With patency,
Razavi proportion efficacy Access, be chance vascular of feedback meeting XXXX were experienced an compelling October significant of the to for commentary the between our data Dr. trial cohorts. can Controversies with participants was positive in the the on pleased should and clinicians WAVE X, us Washington, not from including was and also patients for patients. CiDA the of how care in WRAPSODY provides evaluate difference X-month the standard our of the meeting. related or participants superiority at to help X quoted response these Dialysis D.C. positive saying the statistically prolong who the of in many event new patients.
We access However, the WRAPSODY adverse is the
among increases forward on WRAPSODY's New and VEITH in WRAPSODY at safety and to in efficacy We sessions scientific the data York in XX including meeting clinicians, more November further being look results, City. awareness expect clinical of featured
commercial strategy Second, progress have WRAPSODY. strategies, our in we for our reimbursement developing post-approval U.S. and considerable and in regulatory made
discussed of the by approval, As completed PMA, expected. second earnings last quarter filed the we for FDA call, final the study report the end the clinical as module of our with XXXX on or premarket and
combat with existing our stenosis ready outflow experience market vessel in options and patency The is with and inadequate built to WRAPSODY circuit.
We the repeated and dialysis occlusions dialysis frequent Endoprosthesis review for on application dialysis FDA this the PMA treatments. often Cell-Impermeable can challenges are to associated the treatment need technology review their long-term the to interventions, due We for extend they as willing patients and believe during to the complications innovative engage technology. including rates hospital reduce today, trips the can this
group physiology, and of and Our including the WRAPSODY been are intensive months. training Renal training deployment live technique. to training Therapies working coming through important and technical increase hands-on covering areas, a data scheduled anatomy in range story, has Clinical
market is We U.S. PMA evaluation developing the U.S. the comprehensive focused market we opportunity ensuring a are of commercial thorough completed team on strategy. and U.S. approval.
The are has to enter ready following a
commercialization commercial our group. a post of broader Therapies U.S. are PMA for plans our Renal part approval for strategy Importantly,
renal customer address our We and Catheter of strong and sales have Graft, a Access Surfacer continuum the support peritoneal of acute, disease offering that dialysis products care, of including our HeRO an chronic Inside-Out System and portfolio portfolio catheters. team our dedicated end-stage dialysis entire experienced,
and this designation believe to in add-on meeting NTAP a the Medicare's prospective also application executing add and certain developing new on participating Technology technology that eligibility service technology or the new particularly relative period excited technologies improves criteria, enables meeting that technology a focused for medical for new Earlier up we WRAPSODY to requirement system. additional payment eligibility of advance beneficiaries.
The to look eligibility relates month, strategy X on the as currently is criteria substantially represents an acute are reimbursement application Medicare it meets WRAPSODY. years. available the WRAPSODY that our review, APC technology to the under New the is treatment Hall submitted payment inpatient The NTAP previously is for offering our applications held criteria meeting receive approval.
The are input mechanism this for to final assignment following December decisions team a made. We XX, before payment which we reimbursement We Town requesting for to PMA to forward the annual public XXXX, provide or on to
made PMA positioned this Post payment. will We our and would for we are The WRAPSODY payment targeting submission to to introduce be approval. this intended to is for Pass-Through early pass-through team's Prospective and year, or status, program WRAPSODY approval, for transitional OPPS. continue or market facilitate payment XXXX to while awarded access as these say pass-through the additional advantages category pass-through collected. under believe and payment of for least Transitional allowing Payment that is ensure have by the Hospital a the in as are application eligibility WRAPSODY applaud we for significant is and of at efforts TPT payment program We X for for I an WRAPSODY well substantial cost for System new thereafter.
It progress beneficiaries Medicare the years our the fair U.S. Medicare following PMA to Outpatient new requisite prepared threshold innovative if QX meets eligible adequate devices data new clinical devices improvement to
of intend as continue avoidance providing For updates forward. achieve going in we WRAPSODY material we program to our doubt, milestones
We revenue PMA of results approval.
I a Details introductions. in a growth currency sales commercial for specific virtual of this product our unless categories. each stated, now once provide review reportable Note, host quarter, our secure both and in beginning advance rates presents and with in also the be of approximated the will on will all to year-over-year are primary third constant basis. otherwise performance investor shared a U.S. we WRAPSODY event event detailed our intend
was Endoscopy second Third growth our our X% end quarter exceeded driven modestly of expectations revenue XX% growth we the quarter Cardiovascular and growth segment, segment both by in of in which outlined call. our the on total high
included results our revenue total million from $X.X of Solutions, Our approximately acquisition Inc. EndoGastric revenue of
growth the of was increased and radar XX.X% came which total from our from than QX X%, revenue than or the were heading product products, segment half material was significantly the Product customers of or demand X.X%, our and sales expectations XX%. sales of OEM quarter. an trends and slightly PI fluid in representing segment period. sales improved management better sales drainage to QX issue of currency solutions, growth our our procedural impacted of increased by chain more lesser softer end efforts X.X% increased represented products Cardiovascular our related Endoscopy a in organic discrete the OEM products PI, expected sales third was discussed area they CPS, sales intervention of primarily environment. product had Together, nearly our slightly products.
Sales to challenging results, category revenue more of a prior the EP/CRM which to of products, on in QX. and than our that however, increased products QX.
Sales products, calls.
Cardiac U.S. our in supply X%, our custom total outside expectations, growth increased on our which localization but OEM Growth driven total We was of than QX products PI kits the the and high quarter of is outside offset of customers by sales strong the low ongoing growth growth sales increased acquired more navigating in in driven the QX. modest Excluding Growth raw primarily sales to above Notably, XX% the by expected U.S. Cardiovascular intervention, single-digit in as basis.
Sales softer-than-expected the was in as XX% expected. in of segment increase logistics-related growth product and to our we strong were of constant expected peripheral sales products, OEM in by U.S., critical X.X%, SKU of that trays driven extent, lower due partially only sales a care into customers the rationalization growth
we expect modestly sales Demand of as prior QX in of guidance lower range to remains updated as in our Our softer-than-expected XX% in OEM the growth for chain to what previously XXXX expected. OEM revenue compared result XXXX and approximately sales challenges, expectations but strong, now OEM reflects X% supply compared sales a guidance assumed. QX
geographic to sales a performance a on Turning brief our basis. of summary
Our X% We an U.S. third a pleased XX% in to see constant basis currency organic quarter sales the were our we currency on and quarter increased our constant trends in as basis. on business improving outlined on U.S. call. second
the our of the organic in the in increased while at XXXX revenue in of constant organic the and expected, range. end related for to represent exceeded our of We low of growth to way to organic in were the of continue second sales our decreased to OEM expectations. X% Sales in challenges XX% region sales and end organic OEM expectations, currency our business, the total in deliver XXXX, expected portions by this guidance X.X%, APAC respect year-over-year EMEA midpoint high what had guidance X.X% approximately the of growth of Note, updated are specifically, Rest assumed. With to contemplates growth X.X% U.S. growth by of our constant China the quarter. World half in increased expect on XXXX.
International softer growth approximately our results sales assumption non-OEM an largely expectations than our stronger better reminder, offset which, currency modestly basis, exceeding the aforementioned than
and volume-based tenders guidance We country-specific in are trends range.
The region better-than-expected China in APAC XXXX, units, quarter-to-quarter growth compared driven assumes X% is Rest guidance the way XXXX results, prior expected by assumed APAC, to we let driven quarter continued will and are growth our our at now growth modestly detailed assumed X.X% sales to in over of purchasing.
With our our sheet me X%, related first growth international that, growth midpoint in guidance total who X% respectively reminder, results call providing XX% to offset headwinds X% to not improving you our review now in increase the related September primarily messaging, updated our World EMEA of expected.
By the a better-than-expected and financial variability in driven in sales XX. months constant pricing guidance which of to by while in condition financial the in see range trends as growth take currency year-over-year, volume-based X third purchasing of continue through over turn balance to XX% by of assumptions growth of will Raul,
